Mounjaro held 86.7% of Korea's GLP-1 weight loss market in June, and Hanmi's homegrown Eppe was just approved in five strengths.
Recap by typeshit. Full story at The Korea Herald.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
Mounjaro prescriptions rose 18-fold in 10 months, and Rep. Seo Young-seok says no alerts fire for multi-month supplies or combined use with appetite suppressants.
Experts quoted by TODAY offer practical ways to ease one of the most common side effects people report on GLP-1 medications.
Loading…